MDSpire - Takeaway
FDA & Government News

Lyme Vaccine Advances in Late Trial

Large global study evaluates novel prevention strategy.

Share

  • 1

    PF-07307405 vaccine shows 73% efficacy.

  • 2

    Conducted in high Lyme disease incidence areas.

  • 3

    Vaccine targets OspA protein of Borrelia burgdorferi.

  • 4

    Study included participants ages 5 and older.

  • 5

    Results indicate no safety concerns.

  • 6

    Vaccine induces antibodies to inhibit bacterial migration.

  • 7

    Lyme disease has 476,000 annual diagnoses in the U.S.

  • 8

    Early symptoms include erythema migrans and systemic symptoms.

Original Source(s)

Lyme Vaccine Advances in Late Trial

  • by Kathryn Wighton

  • March 23, 2026

Related Content

Can Shorter TB Prevention Regimens Work?

Randomized study evaluates efficacy, safety, and completion in high-risk patients

Why Copilots Failed in R&D and What Comes Next 

Organizations that benefit most from AI in R&D will be those that align technology with scientific reality

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.